Texas Retina Associates

“Dr. Vaiser was a true pioneer in the field of retina, and his legacy continues to inspire breakthroughs and advancements that are changing lives — all right here in Texas. His vision and hard work helped pave the path for the incredibly talented teams that both Texas Retina and the Retina Foundation have today.” On behalf of the entire Texas Retina team, Dr. Fish recently presented a $2,000 donation to the Retina Foundation to honor the 90th birthday of one of our founders, Dr. Albert Vaiser. Debbie Klein, Dr. Vaiser’s granddaughter, accepted the donation during a gathering of Retina Foundation employees. Learn more about Dr. Vaiser’s incredible leadership and legacy in our latest blog: https://lnkd.in/ewDV3k5X

Coats’ disease is rare congenital, nonhereditary eye disorder where abnormal blood vessels develop behind the retina and can cause partial or full blindness. Dr. Abbey recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant to help reduce the treatment burden of managing cystoid macular edema in a 6-year-old boy with a history of Coats’ disease. Learn more in our latest blog: https://lnkd.in/e_UtPUPw

Can semaglutide — the drug found in Ozempic, Wegovy and Rybelsus — affect your eyes or vision? While clinical studies have demonstrated its effectiveness in treating type 2 diabetes and promoting weight management, they have also documented vision changes in some patients, including blurred vision, worsening diabetic retinopathy and macular complications. In our latest blog, we break down what you should know about these potential side effects: https://lnkd.in/efJkXXTb

This Friday, Dr. Wang will speak at The Ohio State University’s 7th Annual Retina Case Forum as an invited guest lecturer. A devout Ohio State alumnus, he completed both his undergraduate and medical degrees there as well as his residency and continues to give back to the university and its students in several ways. Learn more in our latest blog: https://lnkd.in/enMA7vGP

A recent study published in the Journal of Clinical Oncology highlighted the importance of performing biopsy and advanced genetic analysis using a prognostic biomarker tool called 15-GEP/PRAME to customize follow-up screening protocols for patients with uveal melanoma, a form of eye cancer. Our own Dr. Timothy Fuller co-authored the article and served as a Principal Investigator for the trial. Texas Retina was also one of the largest recruiters for the study. Learn more in our latest blog: https://lnkd.in/ehYbsZHG

Our own Dr. Kothari recently served as a guest on the New Retina Radio podcast where she discussed recent research findings from the Diabetic Retinopathy Clinical Research (DRCR) Network Protocol AC. Specifically, she discussed the risk factors of patients with diabetic macular edema (DME) switching from bevacizumab to aflibercept. Learn more and access a link to the full podcast: https://lnkd.in/e27cnzhp

Our own Dr. Abbey recently became the first in the world to administer a potential new treatment for diabetic macular edema (DME) as part of the Phase Ib LOTUS clinical trial. EB-105 is the world's first pentavalent trispecific antibody designed to target VEGF-A, VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) in DME. Texas Retina is one of only four sites in the U.S. participating in this trial. Learn more in our latest blog: https://lnkd.in/ehZx-kGh

In addition to earning a Senior Honor Award, our own Dr. Anand also presented at the recent American Society of Retina Specialists (ASRS) annual meeting. He highlighted interim results of the Phase II Skyline clinical trial, which is exploring a potential new gene therapy for X-linked retinitis pigmentosa. Learn more: https://lnkd.in/gn7FJrBF

On behalf of the CALM registry study investigators and supporting clinical sites, Dr. Abbey presented real-world outcomes of the fluocinolone acetonide intravitreal implant for non-infectious uveitis of the posterior segment at the recent annual meeting of the American Society of Retina Specialists (ASRS). Learn more in our latest blog: https://lnkd.in/epgFqUdM

At the recent annual meeting of the American Society of Retina Specialists (ASRS), our own Dr. Wang presented initial results of the Phase II NEPTUNE study, which is exploring brepocitnib, a potential new treatment for active non-infectious. Learn more in our latest blog: https://lnkd.in/e5_5BBjm